Viral gene therapy

Converting a virus into a vector the viral life cycle can be divided into two temporally distinct phases: infection and replication. For gene therapy to be successful, an appropriate amount of a therapeutic gene must be delivered into the target tissue without substantial toxicity. Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. For some disorders, long term expression from a relatively small proportion of cells would be sufficient (for example, genetic disorders), whereas other pathologies might require high, but transient, gene expression. For example, gene therapies designed to interfere with a viral infectious process or inhibit the growth of cancer cells by reconstitution of inactivated tumor suppressor genes may require gene transfer into a large fraction of the abnormal cells.

    Related Conference of Viral gene therapy

    October 17-18, 2022

    21st International Conference on Structural Biology

    Barcelona, Spain
    November 15-16, 2022

    3rd Experts Meeting on Plant, Cellular and Molecular Biology

    Budapest, Hungary
    November 21-22, 2022

    4th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada
    May 03-04, 2023

    16th World Congress on Stem Cell Research

    Paris, France
    May 03-04, 2023

    Global Conference on Cell and Gene Therapy

    Paris, France

    Viral gene therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in